Robert Habib, MiNA Therapeutics CEO
Eli Lilly adds a $15M equity sweetener for its platform partner in saRNA
The father-and-son team at MiNA Therapeutics is on a roll.
Just weeks after snagging a $25 million upfront and a treasure map with close to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
